UNSPSC 51384802: Etoricoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H15ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRX4NFY03R, chemically known as 2,3-bipyridine, 5-chloro-6-methyl-3-(4-(methylsulfonyl)phenyl)- but generally known as etoricoxib, which bears US NIH Compound Identifier 123619. European Medicines Agency schedules Etoricoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16429MIG.

UNSPSC 51384802 Etoricoxib, a Commodity code, nominally covers a specific nonsteroidal anti-inflammatory drug (NSAID), but the recent state and local procurement activity under this code shows a significant mismatch: the single identified opportunity is Seminole County, Florida's IFB for naloxone and drug deactivation systems, which bears no relationship to etoricoxib pharmaceutical products. State and local governments' actual purchasing under this code designation appears minimal or misclassified at present.

Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive bidding process, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023, at 2:00 pm. Vendors were required to submit bids electronically, include all shipping and delivery costs in their proposals, and comply with drug-free workplace certification, E-Verify, and insurance requirements. The contract carried an initial two-year term with one-year renewal option and a three-month probationary period. No explicit set-aside or disadvantaged-enterprise designations applied. The procurement was potentially FEMA-funded, subjecting vendors to federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The mismatch between the code's nominal pharmaceutical scope and the actual opportunity solicited suggests either a coding error in the state or local system or minimal recent etoricoxib procurement activity under this designation.